@article{889ea6078221436a8db7d7bb5cfad7be,
title = "Real world experience in the era of first generation protease inhibitors in the treatment of hepatitis C",
abstract = "The treatment for hepatitis C has been revolutionized with the new era of protease inhibitors. Boceprevir (BOC) and telaprevir (TVR) are potent first generation direct acting antivirals which have demonstrated significantly improved response rates compared to interferon and ribavirin in phase III trials. However there are multiple real-life data sets showing increased adverse events and treatment discontinuations compared to clinical trials, especially in the cirrhotic patient. The advent of all oral, non-interferon regimens offers a promising treatment paradigm for hepatitis C infected patients.",
keywords = "Acting, Antivirals, Boceprevir, Direct, Experience, Hepatitis c, Inhibitors, Protease, Real, Telaprevir, Treatment, World",
author = "Hope Hubbard and Eric Lawitz",
note = "Funding Information: Conflict of Interest Dr. Hope Hubbard declares that she has no conflict of interest. Dr. Eric Lawitz has been a consultant for Abbott Laboratories, Achillion Pharmaceuticals, Anadys Pharmaceuticals, Biolex Therapeutics, GlobeImmune, Inhibitex Pharmaceuticals, Merck & Co., Pharmasset, Santaris Pharmaceuticals, Tibotec, and Theravance. He has received grant support/pending grant support from Abbott Laboratories, Achillion Pharmaceuticals, Anadys Pharmaceuticals, Biolex Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, GlobeImmune, Idenix Pharmaceuticals, Idera Pharmaceuticals, Inhibitex Pharmaceuticals, Intercept Pharmaceuticals, Janssen, Medarex, Medtronic, Merck & Co., Novartis, Pharmasset, Roche, Schering-Plough, Santaris Pharmaceuticals, Scynexis Pharmaceuticals, Vertex Pharmaceuticals, ViroChem Pharma, and ZymoGenetics, as well as payment for lectures from Merck, Vertex, and Gilead.",
year = "2013",
month = dec,
doi = "10.1007/s11901-013-0189-z",
language = "English (US)",
volume = "12",
pages = "189--194",
journal = "Current Hepatitis Reports",
issn = "1540-3416",
publisher = "Springer Publishing Company",
number = "4",
}